STOCK TITAN

[Form 4] Merit Medical Systems Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Lynne N. Ward, a director of Merit Medical Systems (MMSI), reported transactions dated 08/11/2025 on a Form 4. The filing shows the exercise of non-qualified stock options with an exercise price of $34.46 and an associated acquisition of 2,433 shares, and a contemporaneous sale of 2,433 shares at $84.8894.

Following the reported activity the form lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares (as reported on separate lines) and indicates 3,000 derivative securities beneficially owned after the transactions, with 5,433 underlying common shares referenced for the options. The form is signed by an attorney-in-fact on 08/12/2025.

Lynne N. Ward, direttrice di Merit Medical Systems (MMSI), ha segnalato operazioni datate 08/11/2025 su un Form 4. La comunicazione mostra l'esercizio di opzioni su azioni non qualificate con un prezzo d'esercizio di $34.46 e l'acquisizione associata di 2,433 azioni, oltre a una contestuale vendita di 2,433 azioni a $84.8894.

A seguito dell'attività riportata, il modulo indica posizioni di proprietà non derivata pari a 15,242 e 12,809 azioni (segnalate su righe separate) e specifica la detenzione beneficiaria di 3,000 strumenti derivati dopo le transazioni, con 5,433 azioni ordinarie sottostanti riferite alle opzioni. Il modulo è firmato da un procuratore il 08/12/2025.

Lynne N. Ward, directora de Merit Medical Systems (MMSI), informó operaciones con fecha 08/11/2025 en un Form 4. El documento muestra el ejercicio de opciones sobre acciones no calificadas con un precio de ejercicio de $34.46 y la adquisición asociada de 2,433 acciones, además de una venta simultánea de 2,433 acciones a $84.8894.

Tras la actividad reportada, el formulario detalla una tenencia beneficiaria no derivada de 15,242 y 12,809 acciones (reportadas en líneas separadas) e indica la titularidad beneficiaria de 3,000 valores derivados después de las transacciones, con 5,433 acciones ordinarias subyacentes referidas por las opciones. El formulario está firmado por un apoderado el 08/12/2025.

Merit Medical Systems(MMSI)의 이사인 Lynne N. Ward는 08/11/2025자 거래를 Form 4로 보고했습니다. 제출서류에는 행사가격 $34.46의 비자격 주식옵션 행사와 이에 따른 2,433주 취득, 그리고 동시에 이뤄진 2,433주의 $84.8894 매도가 포함되어 있습니다.

보고된 거래 이후 양식에는 비파생(Non-derivative) 보유가 15,242주와 12,809주(각기 다른 행에 기재)로 기재되어 있으며, 거래 후 실질적으로 보유한 파생증권이 3,000개이고 옵션과 관련해 5,433주의 기초 보통주가 참조되어 있다고 명시되어 있습니다. 해당 양식은 권한대리인이 08/12/2025에 서명했습니다.

Lynne N. Ward, administratrice de Merit Medical Systems (MMSI), a déclaré des opérations datées du 08/11/2025 sur un Form 4. Le dépôt indique l'exercice d'options sur actions non qualifiées avec un prix d'exercice de $34.46 et l'acquisition correspondante de 2,433 actions, ainsi qu'une vente simultanée de 2,433 actions à $84.8894.

Après ces opérations, le formulaire fait état d'une détention bénéficiaire non dérivée de 15,242 et 12,809 actions (rapportées sur des lignes séparées) et indique la détention bénéficiaire de 3,000 titres dérivés après les transactions, avec 5,433 actions ordinaires sous-jacentes référencées pour les options. Le formulaire est signé par un mandataire le 08/12/2025.

Lynne N. Ward, Direktorin von Merit Medical Systems (MMSI), meldete Transaktionen datiert 08/11/2025 in einem Form 4. Die Einreichung zeigt die Ausübung nicht qualifizierter Aktienoptionen mit einem Ausübungspreis von $34.46 und den damit verbundenen Erwerb von 2,433 Aktien sowie einen gleichzeitigen Verkauf von 2,433 Aktien zu $84.8894.

Nach den gemeldeten Vorgängen listet das Formular eine nicht-derivative wirtschaftliche Beteiligung von 15,242 und 12,809 Aktien (auf getrennten Zeilen angegeben) und weist 3,000 derivative Wertpapierbestände nach den Transaktionen aus, wobei 5,433 zugrunde liegende Stammaktien für die Optionen referenziert werden. Das Formular ist am 08/12/2025 von einem Bevollmächtigten unterzeichnet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine option exercise and simultaneous sale reported; transaction details clearly disclosed.

The Form 4 documents an option exercise at an exercise price of $34.46 and the acquisition of 2,433 shares, followed by a sale of 2,433 shares at $84.8894 on 08/11/2025. Post-transaction holdings are reported as 15,242 and 12,809 common shares on separate non-derivative lines, and 3,000 derivative securities remain beneficially owned with 5,433 underlying shares noted. For investors, this is a clear, standard disclosure of insider option exercise and sale with explicit prices and quantities; there is no additional financial or operational information in this filing to change valuation models.

TL;DR: Insider exercise and sale properly disclosed; signature by an attorney-in-fact is noted.

The reporting person is identified as Director Lynne N. Ward. The Form 4 is completed and signed by an attorney-in-fact (Brian G. Lloyd) on 08/12/2025, and it includes an explanation that the options "become exercisable in equal annual installments of 33% commencing 08/28/2020." The filing meets Section 16 disclosure requirements by itemizing exercise price, sale price, quantities, and resulting beneficial ownership. From a governance perspective, this is a routine, compliant insider disclosure without other governance events disclosed.

Lynne N. Ward, direttrice di Merit Medical Systems (MMSI), ha segnalato operazioni datate 08/11/2025 su un Form 4. La comunicazione mostra l'esercizio di opzioni su azioni non qualificate con un prezzo d'esercizio di $34.46 e l'acquisizione associata di 2,433 azioni, oltre a una contestuale vendita di 2,433 azioni a $84.8894.

A seguito dell'attività riportata, il modulo indica posizioni di proprietà non derivata pari a 15,242 e 12,809 azioni (segnalate su righe separate) e specifica la detenzione beneficiaria di 3,000 strumenti derivati dopo le transazioni, con 5,433 azioni ordinarie sottostanti riferite alle opzioni. Il modulo è firmato da un procuratore il 08/12/2025.

Lynne N. Ward, directora de Merit Medical Systems (MMSI), informó operaciones con fecha 08/11/2025 en un Form 4. El documento muestra el ejercicio de opciones sobre acciones no calificadas con un precio de ejercicio de $34.46 y la adquisición asociada de 2,433 acciones, además de una venta simultánea de 2,433 acciones a $84.8894.

Tras la actividad reportada, el formulario detalla una tenencia beneficiaria no derivada de 15,242 y 12,809 acciones (reportadas en líneas separadas) e indica la titularidad beneficiaria de 3,000 valores derivados después de las transacciones, con 5,433 acciones ordinarias subyacentes referidas por las opciones. El formulario está firmado por un apoderado el 08/12/2025.

Merit Medical Systems(MMSI)의 이사인 Lynne N. Ward는 08/11/2025자 거래를 Form 4로 보고했습니다. 제출서류에는 행사가격 $34.46의 비자격 주식옵션 행사와 이에 따른 2,433주 취득, 그리고 동시에 이뤄진 2,433주의 $84.8894 매도가 포함되어 있습니다.

보고된 거래 이후 양식에는 비파생(Non-derivative) 보유가 15,242주와 12,809주(각기 다른 행에 기재)로 기재되어 있으며, 거래 후 실질적으로 보유한 파생증권이 3,000개이고 옵션과 관련해 5,433주의 기초 보통주가 참조되어 있다고 명시되어 있습니다. 해당 양식은 권한대리인이 08/12/2025에 서명했습니다.

Lynne N. Ward, administratrice de Merit Medical Systems (MMSI), a déclaré des opérations datées du 08/11/2025 sur un Form 4. Le dépôt indique l'exercice d'options sur actions non qualifiées avec un prix d'exercice de $34.46 et l'acquisition correspondante de 2,433 actions, ainsi qu'une vente simultanée de 2,433 actions à $84.8894.

Après ces opérations, le formulaire fait état d'une détention bénéficiaire non dérivée de 15,242 et 12,809 actions (rapportées sur des lignes séparées) et indique la détention bénéficiaire de 3,000 titres dérivés après les transactions, avec 5,433 actions ordinaires sous-jacentes référencées pour les options. Le formulaire est signé par un mandataire le 08/12/2025.

Lynne N. Ward, Direktorin von Merit Medical Systems (MMSI), meldete Transaktionen datiert 08/11/2025 in einem Form 4. Die Einreichung zeigt die Ausübung nicht qualifizierter Aktienoptionen mit einem Ausübungspreis von $34.46 und den damit verbundenen Erwerb von 2,433 Aktien sowie einen gleichzeitigen Verkauf von 2,433 Aktien zu $84.8894.

Nach den gemeldeten Vorgängen listet das Formular eine nicht-derivative wirtschaftliche Beteiligung von 15,242 und 12,809 Aktien (auf getrennten Zeilen angegeben) und weist 3,000 derivative Wertpapierbestände nach den Transaktionen aus, wobei 5,433 zugrunde liegende Stammaktien für die Optionen referenziert werden. Das Formular ist am 08/12/2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ward Lynne N.

(Last) (First) (Middle)
1600 WEST MERIT PARKWAY

(Street)
SOUTH JORDAN UT 84095

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MERIT MEDICAL SYSTEMS INC [ MMSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, No Par Value 08/11/2025 M 2,433 A $34.46 15,242 D
Common Stock, No Par Value 08/11/2025 S 2,433 D $84.8894 12,809 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified stock options (right to buy) $34.46 08/11/2025 M 2,433 08/28/2020(1) 08/28/2026 Common Stock 5,433 $0 3,000 D
Explanation of Responses:
1. Becomes exercisable in equal annual installments of 33% commencing 08/28/2020.
/s/ Brian G. Lloyd, Attorney-in-Fact 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Merit Medical Systems (MMSI)?

The reporting person is Lynne N. Ward, identified as a Director of Merit Medical Systems.

What transactions are reported on the MMSI Form 4 dated 08/11/2025?

The Form reports the exercise of non-qualified stock options (exercise price $34.46) with an acquisition of 2,433 shares and a contemporaneous sale of 2,433 shares at $84.8894.

How many shares and options are reported as beneficially owned after the transactions?

The filing lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares on separate lines, and 3,000 derivative securities beneficially owned following the transactions, with 5,433 underlying common shares noted for the options.

When were the transactions executed and when was the Form 4 signed?

Transactions are dated 08/11/2025, and the Form 4 is signed by an attorney-in-fact on 08/12/2025.

What is the exercisability schedule shown for the options?

The explanation states the options "become exercisable in equal annual installments of 33% commencing 08/28/2020."
Merit Med Sys Inc

NASDAQ:MMSI

MMSI Rankings

MMSI Latest News

MMSI Latest SEC Filings

MMSI Stock Data

5.10B
57.87M
2.23%
109.19%
6.2%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
SOUTH JORDAN